• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2020年使用替诺福韦/恩曲他滨进行暴露前预防的HIV阴性参与者中严重急性呼吸综合征冠状病毒2血清流行率：法国国家艾滋病和病毒性肝炎研究机构PREVENIR及法国国家健康与医学研究院SAPRIS-Sero队列的一项子研究

Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts.

作者信息

Delaugerre Constance, Assoumou Lambert, Maylin Sarah, Minier Marine, Gabassi Audrey, Genin Michèle, Beniguel Lydie, Ghosn Jade, de Lamballerie Xavier, El Mouhebb Mayssam, Costagliola Dominique, Carrat Fabrice, Molina Jean Michel

机构信息

Service de Virologie, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.

Sorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.

出版信息

Open Forum Infect Dis. 2022 Apr 12;9(7):ofac188. doi: 10.1093/ofid/ofac188. eCollection 2022 Jul.

DOI:10.1093/ofid/ofac188
PMID:35791355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9047207/
Abstract

The potential preventive efficacy of tenofovir/emtricitabine on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was assessed in human immunodeficiency virus preexposure prophylaxis (PrEP) users. Prevalence of SARS-CoV-2 immunoglobulin G between May and October 2020 was similar in PrEP users and in a matched population-based cohort, suggesting that tenofovir/emtricitabine has no role in reducing the risk of SARS-CoV-2 acquisition.

摘要

在接受人类免疫缺陷病毒暴露前预防（PrEP）的人群中，评估了替诺福韦/恩曲他滨对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的潜在预防效果。2020年5月至10月期间，PrEP使用者与匹配的基于人群的队列中SARS-CoV-2免疫球蛋白G的流行率相似，这表明替诺福韦/恩曲他滨在降低感染SARS-CoV-2的风险方面没有作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b88/9251655/29c4c14531d4/ofac188f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b88/9251655/29c4c14531d4/ofac188f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b88/9251655/29c4c14531d4/ofac188f1.jpg

相似文献

1
Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts.2020年使用替诺福韦/恩曲他滨进行暴露前预防的HIV阴性参与者中严重急性呼吸综合征冠状病毒2血清流行率：法国国家艾滋病和病毒性肝炎研究机构PREVENIR及法国国家健康与医学研究院SAPRIS-Sero队列的一项子研究
Open Forum Infect Dis. 2022 Apr 12;9(7):ofac188. doi: 10.1093/ofid/ofac188. eCollection 2022 Jul.
2
HIV preexposure prophylaxis: new data and potential use.HIV暴露前预防：新数据及潜在用途。
Top Antivir Med. 2011 Dec;19(5):181-5.
3
Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.每日口服替诺福韦和恩曲他滨替诺福韦预防暴露前用药可降低 HIV-1 未感染的异性恋男性和女性中单纯疱疹病毒 2 型的感染率：一项随机试验的亚组分析。
Ann Intern Med. 2014 Jul 1;161(1):11-9. doi: 10.7326/M13-2471.
4
Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.用于预防HIV的全身性暴露前预防：将临床数据转化为临床实践。
Ann Pharmacother. 2014 Apr;48(4):507-18. doi: 10.1177/1060028014520880. Epub 2014 Jan 28.
5
Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement.HIV 感染预防的暴露前预防：美国预防服务工作组推荐声明。
JAMA. 2019 Jun 11;321(22):2203-2213. doi: 10.1001/jama.2019.6390.
6
HIV Preexposure Prophylaxis: A Review.HIV 暴露前预防：综述。
JAMA. 2018 Mar 27;319(12):1261-1268. doi: 10.1001/jama.2018.1917.
7
Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.HIV 感染预防的暴露前预防：美国预防服务工作组的证据报告和系统评价。
JAMA. 2019 Jun 11;321(22):2214-2230. doi: 10.1001/jama.2019.2591.
8
Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis.基于马拉维若的方案作为 HIV 暴露前预防的疗效预测的转化方法。
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01729-19.
9
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.美国的HIV暴露前预防：对终身感染风险、临床结局及成本效益的影响
Clin Infect Dis. 2009 Mar 15;48(6):806-15. doi: 10.1086/597095.
10
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.恩曲他滨/替诺福韦对HIV阴性者骨矿物质密度影响的随机双盲安慰剂对照试验
Clin Infect Dis. 2015 Aug 15;61(4):572-80. doi: 10.1093/cid/civ324. Epub 2015 Apr 23.

引用本文的文献

1
The 'Informed Matter' of Gay and Bisexual Men's (Potential) Use of HIV Antiretrovirals to Prevent COVID-19.男同性恋者和双性恋者（潜在）使用艾滋病毒抗逆转录病毒药物预防新冠病毒的“知情事项”
Sociol Health Illn. 2025 Sep;47(7):e70078. doi: 10.1111/1467-9566.70078.
2
Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B.恩替卡韦和富马酸替诺福韦二吡呋酯对慢性乙型肝炎患者 COVID-19 发病率和严重程度的影响。
BMC Infect Dis. 2023 Nov 30;23(1):843. doi: 10.1186/s12879-023-08838-0.
3
Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout.

本文引用的文献

1
Diabetes, obesity, hypertension and risk of severe COVID-19: a protocol for systematic review and meta-analysis.糖尿病、肥胖症、高血压与重症新型冠状病毒肺炎风险：一项系统评价与荟萃分析方案
BMJ Open. 2021 Nov 26;11(11):e051711. doi: 10.1136/bmjopen-2021-051711.
2
Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study.抗体状况和法国三个地区成年人在首次封锁后的 SARS-CoV-2 感染累积发生率及相关危险因素：一项多队列研究。
Int J Epidemiol. 2021 Nov 10;50(5):1458-1472. doi: 10.1093/ije/dyab110.
3
Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial.
人类免疫缺陷病毒状况、替诺福韦暴露与新冠肺炎结局不良的风险：疫苗推出前来自 6 个美国队列的真实世界分析。
Clin Infect Dis. 2023 May 24;76(10):1727-1734. doi: 10.1093/cid/ciad084.
替诺福韦酯富马酸盐和恩曲他滨对COVID-19门诊患者鼻咽部严重急性呼吸综合征冠状病毒2病毒载量负担的影响：一项前瞻性、随机、开放标签的2期试验。
EClinicalMedicine. 2021 Aug;38:100993. doi: 10.1016/j.eclinm.2021.100993. Epub 2021 Jun 27.
4
Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort.西班牙艾滋病毒研究网络队列中 SARS-CoV-2 血清阳性率及相关因素分析。
Clin Microbiol Infect. 2021 Nov;27(11):1678-1684. doi: 10.1016/j.cmi.2021.06.023. Epub 2021 Jun 26.
5
Incidence and risk factors of COVID-19-like symptoms in the French general population during the lockdown period: a multi-cohort study.封锁期间法国普通人群中出现 COVID-19 样症状的发生率和危险因素：一项多队列研究。
BMC Infect Dis. 2021 Feb 10;21(1):169. doi: 10.1186/s12879-021-05864-8.
6
Preventive Efficacy of Tenofovir/Emtricitabine Against Severe Acute Respiratory Syndrome Coronavirus 2 Among Pre-Exposure Prophylaxis Users.替诺福韦/恩曲他滨对暴露前预防使用者中严重急性呼吸综合征冠状病毒2的预防效果
Open Forum Infect Dis. 2020 Sep 25;7(11):ofaa455. doi: 10.1093/ofid/ofaa455. eCollection 2020 Nov.
7
Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa.南非西开普省人群队列研究中 2019 冠状病毒病（COVID-19）死亡的危险因素。
Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015. doi: 10.1093/cid/ciaa1198.
8
Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech).评估三种免疫测定法（Euroimmun 和 Abbott 的两种自动化免疫测定法以及 NG Biotech 的一种快速侧向流动免疫测定法）用于诊断 COVID-19 的 SARS-CoV-2 血清学检测。
J Clin Virol. 2020 Aug;129:104511. doi: 10.1016/j.jcv.2020.104511. Epub 2020 Jun 15.
9
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study.接受抗逆转录病毒疗法的 HIV 阳性者中 COVID-19 的发病率和严重程度：一项队列研究。
Ann Intern Med. 2020 Oct 6;173(7):536-541. doi: 10.7326/M20-3689. Epub 2020 Jun 26.
10
A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.一个核苷酸类似物文库可终止由导致非典和新冠肺炎的冠状病毒聚合酶催化的RNA合成。
Antiviral Res. 2020 Aug;180:104857. doi: 10.1016/j.antiviral.2020.104857. Epub 2020 Jun 18.